NASDAQ:VSAR - Versartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.0250 +0.02 (+1.00 %)
(As of 07/23/2018 01:44 AM ET)
Previous Close$2.0250
Today's Range$2.00 - $2.05
52-Week Range$1.35 - $22.10
Volume117,057 shs
Average Volume435,502 shs
Market Capitalization$73.06 million
P/E Ratio-0.84
Dividend YieldN/A
Versartis logoVersartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.09
Current Ratio21.29
Quick Ratio21.29


Trailing P/E Ratio-0.84
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales1,826.55
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book0.88


EPS (Most Recent Fiscal Year)($2.41)
Net Income$-84,970,000.00
Net MarginsN/A
Return on Equity-84.63%
Return on Assets-53.05%


Outstanding Shares36,080,000
Market Cap$73.06

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) issued its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.86) by $0.61. View Versartis' Earnings History.

When is Versartis' next earnings date?

Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Versartis.

What price target have analysts set for VSAR?

9 analysts have issued 12 month price targets for Versartis' shares. Their predictions range from $3.00 to $14.00. On average, they anticipate Versartis' stock price to reach $5.1250 in the next year. This suggests a possible upside of 153.1% from the stock's current price. View Analyst Ratings for Versartis.

What is the consensus analysts' recommendation for Versartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Versartis in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Are investors shorting Versartis?

Versartis saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 936,082 shares, a decrease of 53.3% from the June 15th total of 2,004,665 shares. Based on an average daily volume of 950,622 shares, the days-to-cover ratio is presently 1.0 days. Currently, 3.2% of the shares of the stock are sold short. View Versartis' Current Options Chain.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, CEO, Pres & Director (Age 60)
  • Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. (Age 53)

Has Versartis been receiving favorable news coverage?

News articles about VSAR stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Versartis earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.69 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $2.0250.

How big of a company is Versartis?

Versartis has a market capitalization of $73.06 million and generates $40,000.00 in revenue each year. The biopharmaceutical company earns $-84,970,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Versartis employs 28 workers across the globe.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]

MarketBeat Community Rating for Versartis (NASDAQ VSAR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.